Find information on thousands of medical conditions and prescription drugs.

Loracarbef

Loracarbef is a second-generation cephalosporin antibiotic, also called Lorabid. Its chemical name is (6R,7S)-7--3-chloro-8-oxo-1-azabicyclooct-2-ene-2-carboxylic acid monohydrate. Its empirical formula is C16H16ClN3O4•H2O, and its molecular mass is 367.8.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


British hypertension society guidelines
From Journal of Family Practice, 7/1/04 by B. Williams

* CLINICAL QUESTION

How should hypertension be managed?

* BOTTOM LINE

The British Hypertension Society guidelines (BHS-IV) and the American Joint National Committee guidelines (JNC-7) are very similar in treatment goals. However, the BHS-IV guidelines do not require treatment until both the systolic and diastolic numbers are greater than 160/100 mm Hg, respectively, for patients without cardiovascular disease, diabetes, or other organ damage, whereas the JNC-7 guidelines start drug treatment in all patients with both numbers greater than 140/90 mm Hg. The BHS-IV suggests initial treatment with any 1 of 4 drugs (see the ABCD rule in the synopsis), whereas the bedrock of treatment recommended by the JNC-7 is diuretics, primarily because of the lower cost. (LOE=5)

* STUDY DESIGN

Practice guideline

* SETTING

Various (guideline)

* SYNOPSIS

The British Hypertension Society has issued their fourth update on the treatment of hypertension (BHS-IV). The guidelines give a strength of recommendation on the basis of the quality of evidence, ranging from A (directly based on a meta-analysis of controlled trials) to D (expert recommendation or extrapolation from other data).

The guidelines recommend suggesting lifestyle modification for patients with high normal blood pressure, defined as a 130-139/ 85-89 mm Hg (strength of recommendation [SOR]=A). Treatment of blood pressure in the range of 140-159/90-99 mm Hg requires consideration of the presence of cardiovascular disease, other target organ damage, diabetes mellitus, or an estimated cardiovascular disease risk of at least 20% over 10 years (SOR=A). Drug therapy should begin when the blood pressure is >160/100 mm Hg (SOR=A). The goal of treatment should be a blood pressure of >140/85 mm Hg for nondiabetic patients, and >130/80 mm Hg in diabetic patients (SOR=B).

Initial treatment should be based on the ABCD rule, a mnemonic for remembering that younger (aged <55 years) and nonblack patients will respond better to an Angiotensin-converting enzyme inhibitor or a Beta-blocker, and older patients and blacks of any age will respond better to a Calcium-channel blocker or a Diuretic (SOR=C). If a second drug is needed, it should be from the other category (that is, a patient on an A or B drug should have a C or D drug added, and vice-versa). Many patients will need at least 2 drugs to obtain the necessary blood pressure control.

DRUG BRAND NAMES

Azithromycin * Zithromax

Cefaclor * Ceclor

Clarithromycin * Biaxin

Loracarbef * Lorabid

Metronidazole * Flagyl

0meprazole * Prilosec

Simvastatin * Zocor

Williams B, Poulter NR, Brown MJ, et al. British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634-640.

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Loracarbef
Home Contact Resources Exchange Links ebay